Sander Dale A. 4
4 · Humacyte, Inc. · Filed May 20, 2026
Research Summary
AI-generated summary of this filing
Humacyte (HUMA) CFO Dale A. Sander Sells 45,887 Shares
What Happened
Dale A. Sander, Humacyte’s Chief Financial Officer and Chief Corporate Development Officer, disposed of 45,887 shares of Humacyte common stock on 2026-05-18 at $0.90 per share, generating proceeds of $41,147. This was a sale (not a purchase) and reflects a routine sell-to-cover transaction related to vested restricted stock units, not a discretionary trade for investment purposes.
Key Details
- Transaction date and price: 2026-05-18 at $0.90 per share; total proceeds $41,147.
- Transaction type/code: Sale (S); footnote indicates tax withholding (F) via automated "sell-to-cover."
- Footnote summary: Shares were sold to satisfy statutory tax withholding on vested RSUs under a plan intended to meet Rule 10b5-1(c) affirmative defense conditions; the sale was mandated by issuer practice and not a discretionary sale by the reporting person.
- Filing: Form 4 filed 2026-05-20 for the 2026-05-18 transaction (appears timely).
- Shares owned after transaction: Not specified in the provided filing summary.
Context
Sell-to-cover transactions are common when restricted stock units vest and generally reflect tax withholding needs rather than a signal about the executive’s view on the company. Purchases typically carry more informational weight for investors; this filing documents a routine withholding sale.
Insider Transaction Report
- Sale
Common Stock
[F1]2026-05-18$0.90/sh−45,887$41,147→ 267,213 total
- 40,600(indirect: By Spouse)
Common Stock
Footnotes (1)
- [F1]Represents the number of shares of Common Stock sold under an automated program to cover the statutory tax withholding obligations in connection with the vesting of restricted stock units previously granted to the Reporting Person. This sale was mandated by the Issuer's practice to require the satisfaction of minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction pursuant to a plan entered into by the Reporting Person for the purchase or sale of equity securities of the Issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), and therefore does not represent a discretionary sale by the Reporting Person.